Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Cumberland Pharmaceuticals (CPIX) Debt to Equity: 2009-2024

Historic Debt to Equity for Cumberland Pharmaceuticals (CPIX) over the last 14 years, with Dec 2024 value amounting to $0.67.

  • Cumberland Pharmaceuticals' Debt to Equity fell 69.10% to $0.20 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.19, marking a year-over-year decrease of 51.83%. This contributed to the annual value of $0.67 for FY2024, which is 54.79% up from last year.
  • Per Cumberland Pharmaceuticals' latest filing, its Debt to Equity stood at $0.67 for FY2024, which was up 54.79% from $0.43 recorded in FY2023.
  • Cumberland Pharmaceuticals' 5-year Debt to Equity high stood at $0.67 for FY2024, and its period low was $0.32 during FY2020.
  • Over the past 3 years, Cumberland Pharmaceuticals' median Debt to Equity value was $0.45 (recorded in 2022), while the average stood at $0.52.
  • In the last 5 years, Cumberland Pharmaceuticals' Debt to Equity declined by 11.79% in 2020 and then skyrocketed by 54.79% in 2024.
  • Yearly analysis of 5 years shows Cumberland Pharmaceuticals' Debt to Equity stood at $0.32 in 2020, then grew by 9.75% to $0.35 in 2021, then grew by 27.50% to $0.45 in 2022, then decreased by 3.32% to $0.43 in 2023, then spiked by 54.79% to $0.67 in 2024.